Carlsmed (CARL) Stock Price, News & Analysis

Company Overview

Carlsmed, Inc. is a medical technology company focused on improving outcomes for patients undergoing complex spinal surgery. The company develops personalized implants and surgical solutions designed to help spine surgeons address the anatomical needs of individual patients, particularly those with adult spinal deformity and other challenging spinal conditions.

Its principal product platform, aprevo, uses patient-specific planning and implant design to support spinal reconstruction procedures. The platform includes customized interbody and posterior implants that are manufactured using three-dimensional printing and are intended to help surgeons restore spinal alignment and achieve their procedural objectives.

Carlsmed was founded in 2015 and is headquartered in Carlsbad, California. The company primarily serves spine surgeons, hospitals and patients in the United States, with its products used in specialized spinal procedures. Carlsmed works with healthcare providers to incorporate patient-specific imaging, surgical planning and customized implants into the treatment process.

Key Stats

• Today's Range: $15.28 to $15.76
• 50-Day Range: $10.80 to $16.88
• 52-Week Range: $8.50 to $17.23
• Volume: 16,370 shs
• Average Volume: 140,827 shs
• Market Capitalization: $430.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $19.25
• Consensus Rating: Moderate Buy

Carlsmed Stock Analysis - MarketRank™

Carlsmed scored higher than 54% of companies evaluated by MarketBeat, and ranked 409th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Carlsmed has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Carlsmed has a consensus price target of $19.25, representing about 22.6% upside from its current price of $15.71.

Amount of Analyst Coverage

Carlsmed has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Carlsmed are expected to decrease in the coming year, from ($1.50) to ($1.53) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Carlsmed is -10.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Carlsmed is -10.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Carlsmed has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.63% of the float of Carlsmed has been sold short.

Short Interest Ratio / Days to Cover

Carlsmed has a short interest ratio ("days to cover") of 6.

Change versus previous month

Short interest in Carlsmed has recently decreased by 16.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Carlsmed does not currently pay a dividend.

Dividend Growth

Carlsmed does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.60

News Sentiment

Carlsmed has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Carlsmed this week, compared to 2 articles on an average week.

Search Interest

Only 2 people have searched for CARL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Carlsmed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Carlsmed insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.90% of the stock of Carlsmed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Carlsmed has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/22/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:CARL
• CIK: 1794546
• Web: carlsmed.com
• Phone: (858) 295-9290
• Fax: N/A
• Employees: 127
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Carlsmed: $19.25
• High Price Target: $23.00
• Low Price Target: $17.00
• Potential Upside/Downside: +22.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$29.63 million
• Net Margins: -57.42%
• Pretax Margin: -57.42%
• Return on Equity: -38.06%
• Return on Assets: -28.96%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 8.84
• Quick Ratio: 8.66

Sales & Book Value

• Annual Sales: $50.51 million
• Price / Sales: 8.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.72 per share
• Price / Book: 4.24

Miscellaneous

• Outstanding Shares: 27,300,000
• Free Float: 23,781,000
• Market Cap: $430.38 million
• Optionable: N/A
• Beta: 1.95